Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Clinical Trial
. 2006 Jul 15;108(2):756-62.
doi: 10.1182/blood-2006-01-0233. Epub 2006 Mar 21.

Rituximab for steroid-refractory chronic graft-versus-host disease

Corey Cutler  1 , David Miklos, Haesook T Kim, Nathaniel Treister, Sook-Bin Woo, Don Bienfang, Lloyd B Klickstein, Jesse Levin, Katherine Miller, Carol Reynolds, Rebecca Macdonell, Mildred Pasek, Stephanie J Lee, Vincent Ho, Robert Soiffer, Joseph H Antin, Jerome Ritz, Edwin Alyea
Affiliations
Clinical Trial

Rituximab for steroid-refractory chronic graft-versus-host disease

VSports注册入口 - Corey Cutler et al. Blood. .

V体育平台登录 - Abstract

B cells may be implicated in the pathophysiology of chronic graft-versus-host disease (GVHD), as evidenced by antibody production against sex-mismatched, Y chromosome-encoded minor HLA antigens in association with chronic GVHD. We therefore designed a phase 1/2 study of anti-B-cell therapy with rituximab in steroid-refractory chronic GVHD. Twenty-one patients were treated with 38 cycles of rituximab. Rituximab was tolerated well, and toxicity was limited to infectious events. The clinical response rate was 70%, including 2 patients with complete responses. Responses were limited to patients with cutaneous and musculoskeletal manifestations of chronic GVHD and were durable through 1 year after therapy. The median dose of prednisone among treated subjects fell from 40 mg/day to 10 mg/day, 1 year after rituximab therapy (P < . 001) VSports手机版. A chronic GVHD symptom score improved in the majority of treated patients. Antibody titers against Y chromosome-encoded minor HLA antigens fell and remained low, whereas titers against infectious antigens (EBV, tetanus) remained stable or rose during the treatment period. We conclude that specific anti-B-cell therapy with rituximab may be beneficial for patients with steroidrefractory chronic GVHD. This trial was registered at www. clinicaltrials. gov as #NCT00136396. .

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Serologic responses to rituximab. (A) Normalized antibody titers. The 2 left panels demonstrate the decreasing antibody titers against 2 H-Y antigens, DBY and UTY, in 4 male patients with female donors. Each subject has 5 measurements, including baseline (week 0) after 1 course of rituximab (week 9), after a second course of rituximab (week 17), 6 months after rituximab (week 27), and 1 year after rituximab (week 52). The 2 right panels demonstrate the stable or increasing titers against 2 non–H-Y antigens, EBV and tetanus. The dashed horizontal line represents the baseline level. (B) Box and whisker plot of EBV and tetanus titers in 12 patients. The boxes represent the 25th and 75th percentiles of the antibody titers measured. The whiskers represent the 5th and 95th percentiles of the measured values. The horizontal line within each box is the median antibody titer measured. All comparisons are P = NS.
Figure 2.
Figure 2.
Representative time line of serologic response to rituximab in one patient. The trend in antibody titers against 3 antigens (DBY ♦, UTY ▪, and EBV ▴) before and after administration of rituximab (vertical arrows) is demonstrated by the trend lines (added for clarity). The clinical time course of chronic GVHD is depicted along the x-axis.
See this image and copyright information in PMC

References

    1. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol. 2004;125: 435-454. - "V体育官网" PubMed
    1. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood. 2001;97: 1196-1201. - PubMed
    1. Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100: 48-51. - PubMed
    1. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 2001;28: 121-129. - PubMed
    1. Sutherland HJ, Fyles GM, Adams G, et al. Quality of life following bone marrow transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant. 1997;19: 1129-1136. - PubMed

Publication types (V体育2025版)

MeSH terms

Associated data